melatonin has been researched along with Migraine Disorders in 63 studies
Migraine Disorders: A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)
| Excerpt | Relevance | Reference |
|---|---|---|
| "There is increasing evidence that headache disorders are connected with melatonin secretion and pineal function." | 8.83 | Potential therapeutic use of melatonin in migraine and other headache disorders. ( Cavalheiro, EA; Masruha, MR; Moreira-Filho, CA; Peres, MF; Zukerman, E, 2006) |
| "Headache is a well-documented side effect of indomethacin in the older medical literature; however, it has rarely been commented on in indomethacin-responsive hemicrania continua." | 7.80 | Melatonin responsive hemicrania continua in which indomethacin was associated with contralateral headache. ( Hollingworth, M; Young, TM, 2014) |
| "This was a randomized, double-blind trial of melatonin (3 mg or 6 mg) versus placebo for migraine prevention in 10-17 year-olds with 4-28/28 headache days at baseline." | 5.69 | Melatonin for migraine prevention in children and adolescents: A randomized, double-blind, placebo-controlled trial after single-blind placebo lead-in. ( Allen, IE; Gelfand, AA; Greene, K; Grimes, B; Irwin, S; Powers, SW; Qubty, W; Szperka, CL; Waung, M, 2023) |
| "There is increasing evidence that headache disorders are connected with melatonin secretion and pineal function." | 4.83 | Potential therapeutic use of melatonin in migraine and other headache disorders. ( Cavalheiro, EA; Masruha, MR; Moreira-Filho, CA; Peres, MF; Zukerman, E, 2006) |
| "Headache is a well-documented side effect of indomethacin in the older medical literature; however, it has rarely been commented on in indomethacin-responsive hemicrania continua." | 3.80 | Melatonin responsive hemicrania continua in which indomethacin was associated with contralateral headache. ( Hollingworth, M; Young, TM, 2014) |
| "To assess urinary 6-sulphatoxymelatonin levels in a large consecutive series of patients with migraine and several comorbidities (chronic fatigue, fibromyalgia, insomnia, anxiety, and depression) as compared with controls." | 3.76 | Urinary 6-sulphatoxymelatonin levels are depressed in chronic migraine and several comorbidities. ( Cipolla-Neto, J; de Souza Vieira, DS; Lin, J; Masruha, MR; Minett, TS; Peres, MF; Vilanova, LC; Zukerman, E, 2010) |
| "As an acute treatment for pediatric migraine, both low and high doses of melatonin were associated with pain reduction; however, study drop-out was high." | 2.94 | Melatonin for Acute Treatment of Migraine in Children and Adolescents: A Pilot Randomized Trial. ( Allen, IE; Gelfand, AA; Greene, KA; Irwin, SL; Qubty, WF; Ross, AC, 2020) |
| "Melatonin may prove to be an efficient substitute for sodium valproate, as a chronic migraine prophylaxis." | 2.84 | Use of melatonin versus valproic acid in prophylaxis of migraine patients: A double-blind randomized clinical trial. ( Abdolrazaghnejad, A; Ebrahimi-Monfared, M; Faraji, F; Mohammadbeigi, A; Sharafkhah, M, 2017) |
| "Melatonin therapy in migraine was associated with a significantly higher responder rate when compared to both placebo and standard therapy (OR = 1." | 2.82 | Efficacy and Safety of Melatonin as Prophylaxis for Migraine in Adults: A Meta-analysis. ( Jena, M; Maiti, R; Mishra, A; Mishra, BR; Puliappadamb, HM, 2022) |
| "Migraine is a chronic disease of global concern, regardless of socio-economic and cultural background." | 2.82 | The Pathogenetic Role of Melatonin in Migraine and Its Theoretic Implications for Pharmacotherapy: A Brief Overview of the Research. ( Cegielska, J; Domitrz, I; Zduńska, A, 2022) |
| "Melatonin was superior to amitriptyline in the percentage of patients with a greater than 50% reduction in migraine frequency." | 2.82 | Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention. ( Cipolla-Neto, J; Gonçalves, AL; Martini Ferreira, A; Peres, MF; Ribeiro, RT; Zukerman, E, 2016) |
| " Clinical adverse events were seen in 23." | 2.80 | Safety and efficacy of melatonin in pediatric migraine prophylaxis. ( Fallah, R; Ferdosian, F; Shoroki, FF, 2015) |
| "Men and women, aged 18-65 years, with migraine but otherwise healthy, experiencing 2-7 attacks per month, were recruited from the general population." | 2.75 | Prophylaxis of migraine with melatonin: a randomized controlled trial. ( Alstadhaug, KB; Bekkelund, SI; Odeh, F; Salvesen, R, 2010) |
| "Migraine and sleep disorders are common chronic diseases in the general population, with significant negative social and economic impacts." | 2.72 | Migraine and Sleep-An Unexplained Association? ( Budrewicz, S; Chojdak-Łukasiewicz, J; Nowakowska-Kotas, M; Waliszewska-Prosół, M, 2021) |
| "MLT suppression was more marked in the migraine group than in the control group [difference of area under curve (DeltaAUC)=-53." | 2.71 | Melatonin secretion is supersensitive to light in migraine. ( Borson-Chazot, F; Brun, J; Chazot, G; Chiquet, C; Claustrat, B, 2004) |
| "The NMA demonstrated that migraine prophylaxis with oral melatonin 3 mg/d (immediate-release) at bedtime was associated with the greatest improvement in migraine frequency [mean difference = -1." | 2.66 | The association between melatonin and episodic migraine: A pilot network meta-analysis of randomized controlled trials to compare the prophylactic effects with exogenous melatonin supplementation and pharmacotherapy. ( Carvalho, AF; Chen, TY; Chen, YW; Hsu, CW; Li, DJ; Liang, CS; Lin, PY; Matsuoka, YJ; Shiue, YL; Stubbs, B; Su, KP; Tseng, PT; Tu, YK; Wu, YC; Yang, CP, 2020) |
| "Sleep disorders are commonly reported by those who experience migraine, and migraine and sleep disorders have been reported to be closely associated in cross-sectional studies." | 2.66 | Therapeutic role of melatonin in migraine prophylaxis: Is there a link between sleep and migraine? ( Chu, MK; Kim, BS; Song, TJ, 2020) |
| "Regarding the treatment-prevention of migraine, 7 RCTs and 9 non-randomized studies were retrieved." | 2.66 | Endogenous Melatonin Levels and Therapeutic Use of Exogenous Melatonin in Migraine: Systematic Review and Meta-Analysis. ( Brotis, A; Dardiotis, E; Liampas, I; Siokas, V; Vikelis, M, 2020) |
| "Secondary etiologies for stabbing headaches are part of the differential diagnosis of primary stabbing headache; therefore, it is reasonable to perform neuroimaging." | 2.61 | Primary Stabbing Headache. ( Dilli, E; Murray, D, 2019) |
| "Migraine is one of the most severe and debilitating primary headache disorders." | 2.61 | Therapeutic role of melatonin in migraine prophylaxis: A systematic review. ( Long, R; Zhou, S; Zhu, Y, 2019) |
| "The use of melatonin for migraine showed that (i) reduced the number of days with pain and the analgesic consumption when compared with placebo, (ii) no benefits on headache intensity, number of headache days and analgesics consumption when compared with amitriptyline, (iii) reduced the number of analgesic consumption, the attack frequency and the headache intensity when associated with propranolol plus nortriptyline vs placebo plus propranolol plus nortriptyline, and (iv) no difference for any of the interest outcomes when associated with propranolol plus nortriptyline vs sodium valproate plus propranolol plus nortriptyline." | 2.58 | Melatonin for preventing primary headache: A systematic review. ( Adriano Leal Freitas da Costa, A; de Oliveira Cruz Latorraca, C; Leite Pacheco, R; Luiza Cabrera Martimbianco, A; Riera, R; Vianna Pachito, D, 2018) |
| "Pain is a multidimensional response involving several levels of expression ranging from somatosensory to emotional." | 2.50 | Restless legs syndrome and pain disorders: what's in common? ( Delgado Rodrigues, RN; Goulart, LI; Prieto Peres, MF, 2014) |
| "Models of sleep physiology and insomnia are discussed, along with the potential implications for the chronification of migraine and tension-type headache." | 2.48 | Chronic headaches and insomnia: working toward a biobehavioral model. ( Ong, JC; Park, M, 2012) |
| "Melatonin has been proven to have chronobiotic, antioxidant, antihypertensive, anxiolytic and sedative properties." | 2.47 | Analgesic effects of melatonin: a review of current evidence from experimental and clinical studies. ( Amirian, I; Gögenur, I; Reiter, RJ; Rosenberg, J; Wilhelmsen, M, 2011) |
| "Benign cysts of the gland have been related to headache, although the mechanism of production of this assumed clinical manifestation has not been clearly determined, due to the lack of large prospective studies." | 2.46 | Some questions provoked by a chronic headache (with mixed migraine and cluster headache features) in a woman with a pineal cyst. Answers from a literature review. ( Jiménez-Martínez, MC; Molina-Martínez, FJ; Vives-Pastor, B, 2010) |
| "Melatonin is believed to be a significant element in migraine and in other headache disorders, which has implications for treatment." | 2.46 | Headache endocrinological aspects. ( Prieto Peres, MF; Valença, MM, 2010) |
| "Supporting this view, many migraineurs are susceptible to various environmental triggers that influence the secretion of melatonin from the pineal gland, and many prodromal symptoms are probably generated in the hypothalamus, a brain region that provides input into the pineal gland to modulate the secretion of melatonin." | 2.43 | Role of melatonin in the pathophysiology of migraine: implications for treatment. ( Bigal, ME; Rapoport, AM; Sheftell, F; Tepper, SJ; Vogler, B, 2006) |
| "Several theories attempt to explain migraine etiology." | 2.41 | The therapeutic potential of melatonin in migraines and other headache types. ( Gagnier, JJ, 2001) |
| "The prodromal phase of a migraine attack could be considered a syndrome of functional suprachiasmatic nucleus insufficiency, and other phases a reactive denervation hypersensitivity with the affection of the visual, nociceptive, antinociceptive and cranial vasomotor system." | 2.40 | Role of the suprachiasmatic nucleus in the pathogenesis of migraine attacks. ( Zurak, N, 1997) |
| "In the colic group, defecation difficulty, sensitivity to light/sound, and maternal migraine frequency increased and sleep disruption was typical." | 1.91 | A New Perspective on the Pathogenesis of Infantile Colic: Is Infantile Colic a Biorhythm Disorder? ( Cavdar, Z; Duman, N; Durur, DY; Genc, S; Keskinoglu, P; Ozkan, H; Tufekci, KU; Tuzun Erdogan, F; Ucuncu Egeli, T; Ural, C, 2023) |
| "Melatonin secretion is related to migraine pathophysiology in many different ways." | 1.62 | Variability in melatonin concentration in blood serum of patients with episodic migraine: a pilot study. ( Białobrzewski, M; Cegielska, J; Kochanowski, J; Zduńska, A; Zduński, S, 2021) |
| "Alterations in melatonin secretion in migraine has not been explained." | 1.62 | Melatonin secretion in migraine patients: the current state of knowledge. ( Zielonka, D, 2021) |
| "A prior study in adults with migraine demonstrated a reduction in the urinary metabolic substrate of melatonin (urinary 6-sulfatoxymelatonin; aMT6s) during a migraine." | 1.51 | Preliminary Evidence that Melatonin Is not a Biomarker in Children and Adolescents With Episodic Migraine. ( Allen, IE; Berger, A; Gelfand, AA; Irwin, S; Litwin, J; Qubty, W; Waung, M, 2019) |
| "Melatonin has critical functions in human physiology, and research underscores the importance of melatonin in circadian rhythm, sleep, and mood regulation." | 1.46 | Sleep quality, morningness-eveningness preference, mood profile, and levels of serum melatonin in migraine patients: a case-control study. ( Altaş, M; Aydın, A; Boysan, M; Genç, E; Güngör, DC; Kılınç, İ; Kozak, HH; Özer, N; Turgut, K; Uca, AU, 2017) |
| " Melatonin dosing needed for response ranged from 3 to 30 mg." | 1.42 | How effective is melatonin as a preventive treatment for hemicrania continua? A clinic-based study. ( Rozen, TD, 2015) |
| "The parents of 18 children with migraine completed the Children's Sleep Habits Questionnaire and Pediatric Migraine Disability Assessment Score in Arabic." | 1.40 | Urinary 6-sulphatoxymelatonin levels and sleep disorders in children with migraine. ( Abou-Khadra, MK; Hassan, A; Kishk, NA; Shaker, OG, 2014) |
| "Among patients with migraine, 53% presented pain on the day of the urine samples collection." | 1.35 | Low urinary 6-sulphatoxymelatonin concentrations in acute migraine. ( Cipolla-Neto, J; de Souza Vieira, DS; Masruha, MR; Minett, TS; Peres, MF; Vilanova, LC; Zukerman, E, 2008) |
| "Frequent and recurrent migraine headaches can, over time, pose the additional risks of stroke, brain damage, heart failure and attention deficit." | 1.33 | A chronopharmacological preventive treatment for sleep-related migraine headaches and chronic morning headaches: Nitric oxide supersensitivity can cause sleep-related headaches in a subset of patients. ( Eli, R; Fasciano, JA, 2006) |
| "It is generally accepted that migraine is caused by a primary biochemical disorder of the central nervous system involving neurotransmitters, specifically serotonin." | 1.31 | Melatonin: a significant contributor to the pathogenesis of migraine. ( Toglia, JU, 2001) |
| "Chronic migraine (CM), previously called transformed migraine, is a frequent headache disorder that affects 2%-3% of the general population." | 1.31 | Hypothalamic involvement in chronic migraine. ( Abucham, J; Cipolla-Neto, J; Peres, MF; Sanchez del Rio, M; Seabra, ML; Silberstein, SD; Tufik, S; Zukerman, E, 2001) |
| "Melatonin excretion was further decreased during headache." | 1.29 | Urinary melatonin excretion throughout the ovarian cycle in menstrually related migraine. ( Costelli, P; Fanciullacci, M; Fonzi, S; Marabini, S; Murialdo, G; Parodi, C; Polleri, A; Solinas, GP, 1994) |
| "As migraine has been linked to changes in serotonin (5-HT) functions, the emergence of migraine headaches coincident with the onset of relapse implicates dysregulation of the 5-HT system in the pathophysiology of MS." | 1.29 | The co-occurrence of multiple sclerosis and migraine headache: the serotoninergic link. ( Awerbuch, GI; Sandyk, R, 1994) |
| "When the migraine population--from which the depressive patients were excluded--was divided into male and female subgroups, a decrease in plasma melatonin levels was observed only for the female subgroups." | 1.28 | Nocturnal plasma melatonin levels in migraine: a preliminary report. ( Arnaud, JL; Beorchia, S; Brun, J; Chazot, G; Claustrat, B; Loisy, C, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (3.17) | 18.7374 |
| 1990's | 5 (7.94) | 18.2507 |
| 2000's | 14 (22.22) | 29.6817 |
| 2010's | 30 (47.62) | 24.3611 |
| 2020's | 12 (19.05) | 2.80 |
| Authors | Studies |
|---|---|
| Zduńska, A | 2 |
| Cegielska, J | 2 |
| Domitrz, I | 1 |
| Puliappadamb, HM | 3 |
| Maiti, R | 3 |
| Mishra, A | 3 |
| Jena, M | 3 |
| Mishra, BR | 3 |
| Ucuncu Egeli, T | 1 |
| Tufekci, KU | 1 |
| Ural, C | 1 |
| Durur, DY | 1 |
| Tuzun Erdogan, F | 1 |
| Cavdar, Z | 1 |
| Genc, S | 1 |
| Keskinoglu, P | 1 |
| Duman, N | 1 |
| Ozkan, H | 1 |
| Imai, N | 1 |
| Gelfand, AA | 4 |
| Allen, IE | 3 |
| Grimes, B | 2 |
| Irwin, S | 2 |
| Qubty, W | 3 |
| Greene, K | 1 |
| Waung, M | 2 |
| Powers, SW | 1 |
| Szperka, CL | 1 |
| Anderson, G | 1 |
| Tseng, PT | 1 |
| Yang, CP | 1 |
| Su, KP | 1 |
| Chen, TY | 1 |
| Wu, YC | 1 |
| Tu, YK | 1 |
| Lin, PY | 1 |
| Stubbs, B | 1 |
| Carvalho, AF | 1 |
| Matsuoka, YJ | 1 |
| Li, DJ | 1 |
| Liang, CS | 1 |
| Hsu, CW | 1 |
| Chen, YW | 1 |
| Shiue, YL | 1 |
| Liampas, I | 1 |
| Siokas, V | 1 |
| Brotis, A | 1 |
| Vikelis, M | 1 |
| Dardiotis, E | 1 |
| Ross, AC | 1 |
| Irwin, SL | 1 |
| Greene, KA | 1 |
| Qubty, WF | 1 |
| Song, TJ | 1 |
| Kim, BS | 1 |
| Chu, MK | 1 |
| Zduński, S | 1 |
| Białobrzewski, M | 1 |
| Kochanowski, J | 1 |
| Zielonka, D | 1 |
| Waliszewska-Prosół, M | 1 |
| Nowakowska-Kotas, M | 1 |
| Chojdak-Łukasiewicz, J | 1 |
| Budrewicz, S | 1 |
| Patniyot, I | 1 |
| Pletcher, MJ | 1 |
| Goadsby, PJ | 1 |
| Cummings, SR | 1 |
| Lyon, C | 1 |
| Langner, S | 1 |
| D'Onofrio, F | 1 |
| Raimo, S | 1 |
| Spitaleri, D | 1 |
| Casucci, G | 1 |
| Bussone, G | 1 |
| Ansari, M | 1 |
| Karkhaneh, A | 1 |
| Kheirollahi, A | 1 |
| Emamgholipour, S | 1 |
| Rafiee, MH | 1 |
| Ebrahimi-Monfared, M | 1 |
| Sharafkhah, M | 1 |
| Abdolrazaghnejad, A | 1 |
| Mohammadbeigi, A | 1 |
| Faraji, F | 1 |
| Leite Pacheco, R | 1 |
| de Oliveira Cruz Latorraca, C | 1 |
| Adriano Leal Freitas da Costa, A | 1 |
| Luiza Cabrera Martimbianco, A | 1 |
| Vianna Pachito, D | 1 |
| Riera, R | 1 |
| Long, R | 1 |
| Zhu, Y | 1 |
| Zhou, S | 1 |
| Berger, A | 1 |
| Litwin, J | 1 |
| Boutrid, N | 1 |
| Rahmoune, H | 1 |
| Murray, D | 1 |
| Dilli, E | 1 |
| Abou-Khadra, MK | 1 |
| Kishk, NA | 1 |
| Shaker, OG | 1 |
| Hassan, A | 1 |
| Hollingworth, M | 1 |
| Young, TM | 1 |
| Turbina, LG | 1 |
| Fallah, R | 1 |
| Shoroki, FF | 1 |
| Ferdosian, F | 1 |
| Goulart, LI | 1 |
| Delgado Rodrigues, RN | 1 |
| Prieto Peres, MF | 2 |
| Rozen, TD | 1 |
| Gonçalves, AL | 1 |
| Martini Ferreira, A | 1 |
| Ribeiro, RT | 1 |
| Zukerman, E | 6 |
| Cipolla-Neto, J | 5 |
| Peres, MF | 7 |
| Rosenberg, K | 1 |
| Kozak, HH | 1 |
| Boysan, M | 1 |
| Uca, AU | 1 |
| Aydın, A | 1 |
| Kılınç, İ | 1 |
| Genç, E | 1 |
| Altaş, M | 1 |
| Güngör, DC | 1 |
| Turgut, K | 1 |
| Özer, N | 1 |
| R T Ramirez, R | 1 |
| Poling, MI | 1 |
| deCourten, JF | 1 |
| Chamberlain, RL | 1 |
| Masruha, MR | 3 |
| de Souza Vieira, DS | 2 |
| Minett, TS | 2 |
| Vilanova, LC | 2 |
| Miano, S | 1 |
| Parisi, P | 1 |
| Pelliccia, A | 1 |
| Luchetti, A | 1 |
| Paolino, MC | 1 |
| Villa, MP | 1 |
| Lin, J | 1 |
| Evans, RW | 2 |
| Tabeeva, GR | 2 |
| Molina-Martínez, FJ | 1 |
| Jiménez-Martínez, MC | 1 |
| Vives-Pastor, B | 1 |
| Valença, MM | 1 |
| Alstadhaug, KB | 1 |
| Odeh, F | 1 |
| Salvesen, R | 1 |
| Bekkelund, SI | 1 |
| Wilhelmsen, M | 1 |
| Amirian, I | 1 |
| Reiter, RJ | 1 |
| Rosenberg, J | 1 |
| Gögenur, I | 1 |
| Sergeev, AV | 1 |
| Gromova, SA | 1 |
| Ong, JC | 1 |
| Park, M | 1 |
| Claustrat, B | 5 |
| Brun, J | 4 |
| Chiquet, C | 1 |
| Chazot, G | 4 |
| Borson-Chazot, F | 1 |
| da Cunha Tanuri, F | 1 |
| Moreira, FR | 1 |
| Eli, R | 1 |
| Fasciano, JA | 1 |
| Moreira-Filho, CA | 1 |
| Cavalheiro, EA | 1 |
| Vogler, B | 1 |
| Rapoport, AM | 1 |
| Tepper, SJ | 1 |
| Sheftell, F | 1 |
| Bigal, ME | 1 |
| Taylor, FR | 1 |
| Saddier, P | 1 |
| Murialdo, G | 1 |
| Fonzi, S | 1 |
| Costelli, P | 1 |
| Solinas, GP | 1 |
| Parodi, C | 1 |
| Marabini, S | 1 |
| Fanciullacci, M | 1 |
| Polleri, A | 1 |
| Sandyk, R | 1 |
| Awerbuch, GI | 1 |
| Geoffriau, M | 1 |
| Zaidan, R | 1 |
| Mallo, C | 1 |
| Zurak, N | 1 |
| Tom, B | 1 |
| De Vries, P | 1 |
| Heiligers, JP | 1 |
| Willems, EW | 1 |
| Scalbert, E | 1 |
| Delagrange, P | 1 |
| Saxena, PR | 1 |
| Gagnier, JJ | 1 |
| Toglia, JU | 2 |
| Sanchez del Rio, M | 1 |
| Seabra, ML | 1 |
| Tufik, S | 1 |
| Abucham, J | 1 |
| Silberstein, SD | 1 |
| Durlach, J | 1 |
| Pagès, N | 1 |
| Bac, P | 1 |
| Bara, M | 1 |
| Guiet-Bara, A | 1 |
| Loisy, C | 1 |
| Beorchia, S | 1 |
| Arnaud, JL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of Efficacy and Safety of add-on Alpha-lipoic Acid on Migraine Prophylaxis in Adolescent Population: A Randomized Controlled Trial[NCT04064814] | Phase 4 | 60 participants (Actual) | Interventional | 2019-09-14 | Completed | ||
| "Melatonin for Migraine Prevention in Adolescents: A Pilot Remote Trial: The BRAiN-M Study"[NCT02344316] | Phase 2 | 31 participants (Actual) | Interventional | 2015-05-31 | Completed | ||
| Melatonin for Adolescent Migraine Prevention Study (The MAP Study).[NCT03150797] | Phase 2 | 72 participants (Actual) | Interventional | 2017-08-02 | Terminated (stopped due to Insufficient Fund) | ||
| Effects of Perioperative Melatonin on Sleep, Pain, and Confusion After Joint Replacement Surgery[NCT01505465] | 50 participants (Actual) | Interventional | 2012-02-29 | Completed | |||
| A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches[NCT00391755] | Phase 4 | 4 participants (Actual) | Interventional | 2006-10-31 | Terminated (stopped due to Failure to recruit necessary number of patients.) | ||
| Melatonin for Migraine Prevention (The MMP-study): A Randomized, Double-blind, Cross-over, Placebo-controlled Study of Melatonin in Prophylactic Treatment of Migraine[NCT00849511] | Phase 2 | 48 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of participants that had ≥85% headache diary compliance during weeks 12-16 of the study. (NCT02344316)
Timeframe: Weeks 12-16 of the study
| Intervention | Participants (Count of Participants) |
|---|---|
| Melatonin | 11 |
| Placebo | 10 |
eCAP tack caps will be used to measure medication adherence and the number of openings will be recorded per participant. (NCT02344316)
Timeframe: "during the At Home Active Study Period or Weeks 5-16"
| Intervention | Mean Number of Openings (Mean) |
|---|---|
| Melatonin | 39 |
| Placebo | 60 |
Number of Migraine/Migrainous Days Per 28 Day Period in melatonin group and placebo group as measured using an online/mobile device headache diary. (NCT02344316)
Timeframe: final 4 weeks of treatment
| Intervention | days (Mean) |
|---|---|
| Melatonin | 3.6 |
| Placebo | 4.9 |
Number of minutes to sleep onset as measured by a FitBit. (NCT02344316)
Timeframe: 16 weeks
| Intervention | minutes (Mean) |
|---|---|
| Melatonin | 15.2 |
| Placebo | 17.2 |
Change in mean migraine/migrainous days from weeks 5-8 of single-blind treatment phase to weeks 5-8 of randomized treatment phase for each group. (Medians reported when data were not normally distributed). (NCT03150797)
Timeframe: Weeks 5-8 of single-blind treatment phase to weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | -1 |
| Placebo Oral Capsule | 0 |
Mean CASQ score in weeks 5-8 of randomized treatment phase in melatonin treated group vs. placebo, and in each of the three pair-wise group comparisons. The CASQ is a 16-question instrument that uses Likert-like responses and has a score range from 16-80; higher scores indicate greater sleepiness (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | points (Mean) |
|---|---|
| Melatonin 3mg | 33 |
| Melatonin 6mg | 36 |
| Placebo Oral Capsule | 28 |
Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin 3 mg vs. placebo. (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | 2 |
| Placebo Oral Capsule | 2 |
Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin 6 mg vs. melatonin 3 mg. (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | 2 |
| Placebo Oral Capsule | 2 |
Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin 6 mg vs. placebo. (Medians reported when data were not normally distributed). (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | 2 |
| Placebo Oral Capsule | 2 |
Mean migraine/migrainous days in weeks 5-8 of randomized treatment phase in melatonin treated participants vs. placebo. (Ultimately, as the data were not normally distributed, medians were more appropriate). (NCT03150797)
Timeframe: weeks 5-8 of randomized treatment phase
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 2 |
| Melatonin 6mg | 2 |
| Placebo Oral Capsule | 2 |
Number of days acute medication is used in weeks 5-8 of randomized treatment phase in melatonin treated group vs. placebo, and in each of the three pair-wise group comparisons. This refers to the number of days that medication for the acute treatment of headache was used during the time frame. (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 5 |
| Melatonin 6mg | 3 |
| Placebo Oral Capsule | 3 |
Number of headache days in weeks 5-8 of randomized treatment phase in melatonin treated group vs. placebo, and in each of the three pair-wise group comparisons. This refers to number of headache days during the time period--regardless of whether they were migraine or not. (NCT03150797)
Timeframe: Weeks 5-8 of randomized treatment phase.
| Intervention | days (Median) |
|---|---|
| Melatonin 3mg | 8 |
| Melatonin 6mg | 4 |
| Placebo Oral Capsule | 5 |
Sleep time change from 96 hours before surgery to 72 hours after surgery (NCT01505465)
Timeframe: 96 hours before surgery to 72 hours after surgery
| Intervention | minutes (Mean) |
|---|---|
| Study: Melatonin | 20 |
| Control: Placebo | -55 |
27 reviews available for melatonin and Migraine Disorders
| Article | Year |
|---|---|
The Pathogenetic Role of Melatonin in Migraine and Its Theoretic Implications for Pharmacotherapy: A Brief Overview of the Research.
Topics: Female; Headache; Humans; Melatonin; Menstrual Cycle; Migraine Disorders; Pineal Gland | 2022 |
Efficacy and Safety of Melatonin as Prophylaxis for Migraine in Adults: A Meta-analysis.
Topics: Adult; Amitriptyline; Analgesics; Humans; Melatonin; Migraine Disorders; Valproic Acid | 2022 |
Efficacy and Safety of Melatonin as Prophylaxis for Migraine in Adults: A Meta-analysis.
Topics: Adult; Amitriptyline; Analgesics; Humans; Melatonin; Migraine Disorders; Valproic Acid | 2022 |
Efficacy and Safety of Melatonin as Prophylaxis for Migraine in Adults: A Meta-analysis.
Topics: Adult; Amitriptyline; Analgesics; Humans; Melatonin; Migraine Disorders; Valproic Acid | 2022 |
Efficacy and Safety of Melatonin as Prophylaxis for Migraine in Adults: A Meta-analysis.
Topics: Adult; Amitriptyline; Analgesics; Humans; Melatonin; Migraine Disorders; Valproic Acid | 2022 |
Molecular and Cellular Neurobiology of Circadian and Circannual Rhythms in Migraine: A Narrative Review.
Topics: Calcitonin Gene-Related Peptide; Circadian Rhythm; Humans; Melatonin; Migraine Disorders; Neurobiolo | 2023 |
Integrating Pathophysiology in Migraine: Role of the Gut Microbiome and Melatonin.
Topics: Astrocytes; Dysbiosis; Gastrointestinal Microbiome; Humans; Melatonin; Migraine Disorders; Mitochond | 2019 |
The association between melatonin and episodic migraine: A pilot network meta-analysis of randomized controlled trials to compare the prophylactic effects with exogenous melatonin supplementation and pharmacotherapy.
Topics: Dietary Supplements; Female; Humans; Male; Melatonin; Migraine Disorders; Network Meta-Analysis; Pil | 2020 |
Endogenous Melatonin Levels and Therapeutic Use of Exogenous Melatonin in Migraine: Systematic Review and Meta-Analysis.
Topics: Adult; Child; Humans; Melatonin; Migraine Disorders | 2020 |
Therapeutic role of melatonin in migraine prophylaxis: Is there a link between sleep and migraine?
Topics: Central Nervous System Depressants; Comorbidity; Humans; Melatonin; Migraine Disorders; Sleep Wake D | 2020 |
Migraine and Sleep-An Unexplained Association?
Topics: Brain Stem; Cerebral Cortex; Dopamine; Humans; Hypothalamus; Melatonin; Migraine Disorders; Orexins; | 2021 |
Usefulness of nutraceuticals in migraine prophylaxis.
Topics: Dietary Supplements; Humans; Magnesium; Melatonin; Migraine Disorders; Pre-Exposure Prophylaxis; Rib | 2017 |
Melatonin for preventing primary headache: A systematic review.
Topics: Acetaminophen; Analgesics; Aspirin; Central Nervous System Depressants; Humans; Melatonin; Migraine | 2018 |
Therapeutic role of melatonin in migraine prophylaxis: A systematic review.
Topics: Central Nervous System Depressants; Humans; Melatonin; Migraine Disorders; Observational Studies as | 2019 |
Primary Stabbing Headache.
Topics: Comorbidity; Diagnosis, Differential; Female; Headache Disorders, Primary; Humans; Indomethacin; Mal | 2019 |
Restless legs syndrome and pain disorders: what's in common?
Topics: Calcium Channel Blockers; Diagnosis, Differential; Dopamine Agonists; Fibromyalgia; gamma-Aminobutyr | 2014 |
[Chronobiology of migraine].
Topics: Circadian Rhythm; Humans; Hypothalamus; Melatonin; Migraine Disorders; Periodicity | 2010 |
Some questions provoked by a chronic headache (with mixed migraine and cluster headache features) in a woman with a pineal cyst. Answers from a literature review.
Topics: Chronic Disease; Cluster Headache; Cysts; Female; Humans; Melatonin; Middle Aged; Migraine Disorders | 2010 |
Headache endocrinological aspects.
Topics: Animals; Circadian Rhythm; Headache; Headache Disorders; Headache Disorders, Primary; Humans; Melato | 2010 |
Analgesic effects of melatonin: a review of current evidence from experimental and clinical studies.
Topics: Analgesics; Animals; Disease Models, Animal; Fibromyalgia; Humans; Irritable Bowel Syndrome; Male; M | 2011 |
[New aspects of neurobiology of migraine: the role of hypothalamic-pineal system].
Topics: Circadian Rhythm; Humans; Hypothalamus; Melatonin; Migraine Disorders; Pineal Gland | 2011 |
Chronic headaches and insomnia: working toward a biobehavioral model.
Topics: Actigraphy; Adaptation, Psychological; Caffeine; Chronobiology Phenomena; Comorbidity; Headache Diso | 2012 |
Potential therapeutic use of melatonin in migraine and other headache disorders.
Topics: Animals; Headache Disorders; Humans; Melatonin; Migraine Disorders | 2006 |
Role of melatonin in the pathophysiology of migraine: implications for treatment.
Topics: Animals; Clinical Trials as Topic; Humans; Melatonin; Migraine Disorders | 2006 |
"Natural" or alternative medications for migraine prevention.
Topics: Antioxidants; Coenzymes; Complementary Therapies; Female; Herbal Medicine; Humans; Magnesium; Melato | 2006 |
[Disruptions of circadian rhythm in neurologic disorders].
Topics: Autonomic Nervous System Diseases; Body Temperature Regulation; Brain Neoplasms; Central Nervous Sys | 2006 |
Role of the suprachiasmatic nucleus in the pathogenesis of migraine attacks.
Topics: Biological Clocks; Humans; Melatonin; Migraine Disorders; Pineal Gland; Serotonin; Sleep; Suprachias | 1997 |
The therapeutic potential of melatonin in migraines and other headache types.
Topics: Female; Headache Disorders; Humans; Male; Melatonin; Migraine Disorders; Pineal Gland | 2001 |
Biorhythms and possible central regulation of magnesium status, phototherapy, darkness therapy and chronopathological forms of magnesium depletion.
Topics: Biological Clocks; Fatigue; Fibromyalgia; Humans; Light; Magnesium; Magnesium Deficiency; Melatonin; | 2002 |
Is migraine due to a deficiency of pineal melatonin?
Topics: Animals; Circadian Rhythm; Humans; Lighting; Melatonin; Migraine Disorders; Norepinephrine; Pineal G | 1986 |
12 trials available for melatonin and Migraine Disorders
| Article | Year |
|---|---|
Melatonin for migraine prevention in children and adolescents: A randomized, double-blind, placebo-controlled trial after single-blind placebo lead-in.
Topics: Adolescent; Adult; Child; Double-Blind Method; Headache; Humans; Melatonin; Migraine Disorders; Sing | 2023 |
Melatonin for Acute Treatment of Migraine in Children and Adolescents: A Pilot Randomized Trial.
Topics: Acute Disease; Adolescent; Central Nervous System Depressants; Child; Child, Preschool; Female; Huma | 2020 |
Home-Based Trials in Adolescent Migraine: A Randomized Clinical Trial.
Topics: Adolescent; Double-Blind Method; Feasibility Studies; Humans; Melatonin; Migraine Disorders; Patient | 2017 |
Use of melatonin versus valproic acid in prophylaxis of migraine patients: A double-blind randomized clinical trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics; Central Nervous System Agents; Disability Ev | 2017 |
Safety and efficacy of melatonin in pediatric migraine prophylaxis.
Topics: Adolescent; Antioxidants; Child; Child, Preschool; Disability Evaluation; Female; Humans; Male; Mela | 2015 |
Safety and efficacy of melatonin in pediatric migraine prophylaxis.
Topics: Adolescent; Antioxidants; Child; Child, Preschool; Disability Evaluation; Female; Humans; Male; Mela | 2015 |
Safety and efficacy of melatonin in pediatric migraine prophylaxis.
Topics: Adolescent; Antioxidants; Child; Child, Preschool; Disability Evaluation; Female; Humans; Male; Mela | 2015 |
Safety and efficacy of melatonin in pediatric migraine prophylaxis.
Topics: Adolescent; Antioxidants; Child; Child, Preschool; Disability Evaluation; Female; Humans; Male; Mela | 2015 |
Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention.
Topics: Adolescent; Adult; Aged; Amitriptyline; Double-Blind Method; Female; Follow-Up Studies; Humans; Male | 2016 |
Melatonin: Safe And Effective for the Prevention of Migraine Headache.
Topics: Adolescent; Adult; Aged; Amitriptyline; Antidepressive Agents, Tricyclic; Antioxidants; Humans; Mela | 2016 |
Melatonin to prevent migraine or tension-type headache in children.
Topics: Adolescent; Age Factors; Central Nervous System Depressants; Child; Consciousness Disorders; Female; | 2008 |
Prophylaxis of migraine with melatonin: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Antioxidants; Cross-Over Studies; Double-Blind Method; Drug Administration | 2010 |
Melatonin secretion is supersensitive to light in migraine.
Topics: Circadian Rhythm; Female; Humans; Melatonin; Migraine Disorders; Photophobia; Radioimmunoassay | 2004 |
Melatonin, 3 mg, is effective for migraine prevention.
Topics: Adult; Alopecia; Analgesics; Disorders of Excessive Somnolence; Female; Humans; Libido; Male; Melato | 2004 |
Melatonin, 3 mg, is effective for migraine prevention.
Topics: Adult; Alopecia; Analgesics; Disorders of Excessive Somnolence; Female; Humans; Libido; Male; Melato | 2004 |
Melatonin, 3 mg, is effective for migraine prevention.
Topics: Adult; Alopecia; Analgesics; Disorders of Excessive Somnolence; Female; Humans; Libido; Male; Melato | 2004 |
Melatonin, 3 mg, is effective for migraine prevention.
Topics: Adult; Alopecia; Analgesics; Disorders of Excessive Somnolence; Female; Humans; Libido; Male; Melato | 2004 |
Melatonin, 3 mg, is effective for migraine prevention.
Topics: Adult; Alopecia; Analgesics; Disorders of Excessive Somnolence; Female; Humans; Libido; Male; Melato | 2004 |
Melatonin, 3 mg, is effective for migraine prevention.
Topics: Adult; Alopecia; Analgesics; Disorders of Excessive Somnolence; Female; Humans; Libido; Male; Melato | 2004 |
Melatonin, 3 mg, is effective for migraine prevention.
Topics: Adult; Alopecia; Analgesics; Disorders of Excessive Somnolence; Female; Humans; Libido; Male; Melato | 2004 |
Melatonin, 3 mg, is effective for migraine prevention.
Topics: Adult; Alopecia; Analgesics; Disorders of Excessive Somnolence; Female; Humans; Libido; Male; Melato | 2004 |
Melatonin, 3 mg, is effective for migraine prevention.
Topics: Adult; Alopecia; Analgesics; Disorders of Excessive Somnolence; Female; Humans; Libido; Male; Melato | 2004 |
Nocturnal melatonin excretion is decreased in patients with migraine without aura attacks associated with menses.
Topics: Adult; Circadian Rhythm; Darkness; Female; Humans; Melatonin; Menstruation; Migraine Disorders; Refe | 1995 |
24 other studies available for melatonin and Migraine Disorders
| Article | Year |
|---|---|
A New Perspective on the Pathogenesis of Infantile Colic: Is Infantile Colic a Biorhythm Disorder?
Topics: Circadian Rhythm; Colic; Humans; Hydrocortisone; Infant; Melatonin; Migraine Disorders; Prospective | 2023 |
Variability in melatonin concentration in blood serum of patients with episodic migraine: a pilot study.
Topics: Female; Humans; Male; Melatonin; Migraine Disorders; Pilot Projects; Poland; Serum | 2021 |
Melatonin secretion in migraine patients: the current state of knowledge.
Topics: Bodily Secretions; Circadian Rhythm; Humans; Melatonin; Migraine Disorders; Pilot Projects | 2021 |
PURLs: Consider melatonin for migraine prevention.
Topics: Antioxidants; Humans; Melatonin; Migraine Disorders; Nonprescription Drugs; Randomized Controlled Tr | 2017 |
The effect of melatonin on gene expression of calcitonin gene-related peptide and some proinflammatory mediators in patients with pure menstrual migraine.
Topics: Adult; Anti-Inflammatory Agents; Calcitonin Gene-Related Peptide; Cells, Cultured; Female; Gene Expr | 2017 |
Preliminary Evidence that Melatonin Is not a Biomarker in Children and Adolescents With Episodic Migraine.
Topics: Adolescent; Biomarkers; Child; Child, Preschool; Female; Humans; Male; Melatonin; Migraine Disorders | 2019 |
"3M": Migraine, Microbiota and Melatonin.
Topics: Gastrointestinal Diseases; Gastrointestinal Microbiome; Humans; Melatonin; Migraine Disorders | 2019 |
Urinary 6-sulphatoxymelatonin levels and sleep disorders in children with migraine.
Topics: Chi-Square Distribution; Child; Child, Preschool; Circadian Rhythm; Disability Evaluation; Female; H | 2014 |
Melatonin responsive hemicrania continua in which indomethacin was associated with contralateral headache.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Central Nervous System Depressants; Female; Headache; Human | 2014 |
[The use of agomelatine for the preventive treatment of migraine].
Topics: Acetamides; Adult; Female; Humans; Hypnotics and Sedatives; Melatonin; Middle Aged; Migraine Disorde | 2014 |
How effective is melatonin as a preventive treatment for hemicrania continua? A clinic-based study.
Topics: Adult; Aged; Central Nervous System Depressants; Female; Humans; Magnetic Resonance Angiography; Mag | 2015 |
Sleep quality, morningness-eveningness preference, mood profile, and levels of serum melatonin in migraine patients: a case-control study.
Topics: Adult; Affect; Case-Control Studies; Circadian Rhythm; Enzyme-Linked Immunosorbent Assay; Female; Hu | 2017 |
Potential positive feedback loop of pineal cyst and posttraumatic stress disorder.
Topics: Adult; Brain Neoplasms; Cysts; Female; Homeostasis; Humans; Incidental Findings; Magnetic Resonance | 2017 |
Low urinary 6-sulphatoxymelatonin concentrations in acute migraine.
Topics: Acute Disease; Adolescent; Adult; Aged; Chi-Square Distribution; Enzyme-Linked Immunosorbent Assay; | 2008 |
Low urinary 6-sulphatoxymelatonin concentrations in acute migraine.
Topics: Acute Disease; Adolescent; Adult; Aged; Chi-Square Distribution; Enzyme-Linked Immunosorbent Assay; | 2008 |
Low urinary 6-sulphatoxymelatonin concentrations in acute migraine.
Topics: Acute Disease; Adolescent; Adult; Aged; Chi-Square Distribution; Enzyme-Linked Immunosorbent Assay; | 2008 |
Low urinary 6-sulphatoxymelatonin concentrations in acute migraine.
Topics: Acute Disease; Adolescent; Adult; Aged; Chi-Square Distribution; Enzyme-Linked Immunosorbent Assay; | 2008 |
Urinary 6-sulphatoxymelatonin levels are depressed in chronic migraine and several comorbidities.
Topics: Adolescent; Adult; Aged; Anxiety Disorders; Biomarkers; Comorbidity; Depressive Disorder; Down-Regul | 2010 |
Urinary 6-sulphatoxymelatonin levels are depressed in chronic migraine and several comorbidities.
Topics: Adolescent; Adult; Aged; Anxiety Disorders; Biomarkers; Comorbidity; Depressive Disorder; Down-Regul | 2010 |
Urinary 6-sulphatoxymelatonin levels are depressed in chronic migraine and several comorbidities.
Topics: Adolescent; Adult; Aged; Anxiety Disorders; Biomarkers; Comorbidity; Depressive Disorder; Down-Regul | 2010 |
Urinary 6-sulphatoxymelatonin levels are depressed in chronic migraine and several comorbidities.
Topics: Adolescent; Adult; Aged; Anxiety Disorders; Biomarkers; Comorbidity; Depressive Disorder; Down-Regul | 2010 |
Headaches and pineal cysts.
Topics: Adult; Central Nervous System Cysts; Chronic Disease; Disease Progression; Gonadal Steroid Hormones; | 2010 |
A chronopharmacological preventive treatment for sleep-related migraine headaches and chronic morning headaches: Nitric oxide supersensitivity can cause sleep-related headaches in a subset of patients.
Topics: Antioxidants; Headache Disorders; Humans; Hydrocortisone; Melatonin; Migraine Disorders; Moclobemide | 2006 |
Urinary melatonin excretion throughout the ovarian cycle in menstrually related migraine.
Topics: Adult; Circadian Rhythm; Female; Humans; Luteal Phase; Melatonin; Menstrual Cycle; Menstruation Dist | 1994 |
The co-occurrence of multiple sclerosis and migraine headache: the serotoninergic link.
Topics: Adult; Aged; Blood-Brain Barrier; Brain; Calcinosis; Female; Humans; Melatonin; Methylprednisolone; | 1994 |
Nocturnal plasma melatonin profile and melatonin kinetics during infusion in status migrainosus.
Topics: Adult; Case-Control Studies; Circadian Rhythm; Female; Humans; Infusions, Intravenous; Melatonin; Mi | 1997 |
The lack of vasoconstrictor effect of the pineal hormone melatonin in an animal model predictive of antimigraine activity.
Topics: Animals; Antioxidants; Blood Pressure; Carotid Arteries; Disease Models, Animal; Dose-Response Relat | 2001 |
Melatonin: a significant contributor to the pathogenesis of migraine.
Topics: Humans; Melatonin; Migraine Disorders; Pineal Gland; Serotonin | 2001 |
Hypothalamic involvement in chronic migraine.
Topics: Adult; Anxiety; Case-Control Studies; Chronic Disease; Chronobiology Disorders; Circadian Rhythm; Co | 2001 |
Nocturnal plasma melatonin levels in migraine: a preliminary report.
Topics: Adult; Circadian Rhythm; Female; Humans; Male; Melatonin; Middle Aged; Migraine Disorders; Pineal Gl | 1989 |